Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines

Maria A. Pelidis, Michael A Carducci, Jonathan W. Simons

Research output: Contribution to journalArticle

Abstract

Sodium phenylbutyrate (NaPB) is used in urea cycle disorders. We screened 6 neuroblastoma cell lines for in vitro potency of NaPB as an antiproliferative agent, evaluated multiple dosing schedules, and assessed its activity in combination with clinically active agents for neuroblastoma. We determined that NaPB achieves a 30-80% growth inhibition at 5 mM. Repeated dosing and prolonged drug exposure enhanced the cytotoxic effect. NaPB had additive cytotoxic effects when administered with vincristine; however, NaPB did not affect the activity of etoposide, adriamycin, 4-hydroxy- cyclophosphamide or cisplatinum. These results suggest that NaPB is an active agent against neuroblastoma and could be combined with vincristine in novel chemotherapy regimens.

Original languageEnglish (US)
Pages (from-to)889-893
Number of pages5
JournalInternational Journal of Oncology
Volume12
Issue number4
StatePublished - Apr 1998

Fingerprint

Neuroblastoma
Vincristine
Cell Line
Inborn Urea Cycle Disorder
Etoposide
Doxorubicin
Cyclophosphamide
Appointments and Schedules
Drug Therapy
Growth
Pharmaceutical Preparations
4-phenylbutyric acid

Keywords

  • Differentiation
  • Growth inhibition
  • Neuroblastoma
  • Sodium phenylbutyrate
  • Vincristine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines. / Pelidis, Maria A.; Carducci, Michael A; Simons, Jonathan W.

In: International Journal of Oncology, Vol. 12, No. 4, 04.1998, p. 889-893.

Research output: Contribution to journalArticle

@article{4b963cfbfa894fa3b1969202dfdf6318,
title = "Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines",
abstract = "Sodium phenylbutyrate (NaPB) is used in urea cycle disorders. We screened 6 neuroblastoma cell lines for in vitro potency of NaPB as an antiproliferative agent, evaluated multiple dosing schedules, and assessed its activity in combination with clinically active agents for neuroblastoma. We determined that NaPB achieves a 30-80{\%} growth inhibition at 5 mM. Repeated dosing and prolonged drug exposure enhanced the cytotoxic effect. NaPB had additive cytotoxic effects when administered with vincristine; however, NaPB did not affect the activity of etoposide, adriamycin, 4-hydroxy- cyclophosphamide or cisplatinum. These results suggest that NaPB is an active agent against neuroblastoma and could be combined with vincristine in novel chemotherapy regimens.",
keywords = "Differentiation, Growth inhibition, Neuroblastoma, Sodium phenylbutyrate, Vincristine",
author = "Pelidis, {Maria A.} and Carducci, {Michael A} and Simons, {Jonathan W.}",
year = "1998",
month = "4",
language = "English (US)",
volume = "12",
pages = "889--893",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines

AU - Pelidis, Maria A.

AU - Carducci, Michael A

AU - Simons, Jonathan W.

PY - 1998/4

Y1 - 1998/4

N2 - Sodium phenylbutyrate (NaPB) is used in urea cycle disorders. We screened 6 neuroblastoma cell lines for in vitro potency of NaPB as an antiproliferative agent, evaluated multiple dosing schedules, and assessed its activity in combination with clinically active agents for neuroblastoma. We determined that NaPB achieves a 30-80% growth inhibition at 5 mM. Repeated dosing and prolonged drug exposure enhanced the cytotoxic effect. NaPB had additive cytotoxic effects when administered with vincristine; however, NaPB did not affect the activity of etoposide, adriamycin, 4-hydroxy- cyclophosphamide or cisplatinum. These results suggest that NaPB is an active agent against neuroblastoma and could be combined with vincristine in novel chemotherapy regimens.

AB - Sodium phenylbutyrate (NaPB) is used in urea cycle disorders. We screened 6 neuroblastoma cell lines for in vitro potency of NaPB as an antiproliferative agent, evaluated multiple dosing schedules, and assessed its activity in combination with clinically active agents for neuroblastoma. We determined that NaPB achieves a 30-80% growth inhibition at 5 mM. Repeated dosing and prolonged drug exposure enhanced the cytotoxic effect. NaPB had additive cytotoxic effects when administered with vincristine; however, NaPB did not affect the activity of etoposide, adriamycin, 4-hydroxy- cyclophosphamide or cisplatinum. These results suggest that NaPB is an active agent against neuroblastoma and could be combined with vincristine in novel chemotherapy regimens.

KW - Differentiation

KW - Growth inhibition

KW - Neuroblastoma

KW - Sodium phenylbutyrate

KW - Vincristine

UR - http://www.scopus.com/inward/record.url?scp=0031939919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031939919&partnerID=8YFLogxK

M3 - Article

C2 - 9499451

AN - SCOPUS:0031939919

VL - 12

SP - 889

EP - 893

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -